Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$5.50
▲ $0.10 (+1.9%)
Market data updated: 09/20 06:47 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$809.59M
Day Range
$5.36 - $5.54
52-Week Range
$1.74 - $6.60
Beta
—
Next Earnings
04.11.2026
Support
$4.97
Resistance
$6.60
ACRS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+182.1% (1Y)
Strengths: 8/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 69.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$5.09 vs. price $5.50 (-192.6%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
42
Value
38
Momentum
38
Risk
40
Sentiment
100
Fundamental
35
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Aclaris Therapeutics has centered on its financial and regulatory progress. The company received **Fast Track designation** for **modzatinib (ATI-2138)** in treating moderate to severe lichen planus, signaling potential accelerated development. Analysts, including **Canaccord Genuity**, issued **Buy ratings** with an optimistic **$10 price target**, while some forecasts suggested a **69.2% stock rally potential**. Despite reporting a **Q2 loss**, Aclaris **exceeded revenue estimates**, reinforcing investor interest in its pipeline and growth prospects.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Aclaris Therapeutics, Inc.. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
37
🎯 Conviction (vs. Emotion)
24
Psychology
41
Fundamentals
35
Technical
38
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+22%
Market Narrative
54
Fundamental Reality
24
Narrative Gap
+30
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant **Confirmation Bias** (score 46) suggests investors are selectively interpreting data to align with a preexisting narrative, despite worsening fundamentals. The **narrative gap** (+35) and positive sentiment (100/100) contrast sharply with deteriorating revenue (-0.6%) and margins (-2.2pp), indicating a disconnect between perception and reality. **Euphoria** (score 40) further reflects detachment from price momentum, as the stock remains +25.5% above its 200-day average despite negative ROC. The key question is whether this bias will persist or if deteriorating fundamentals will force a reassessment. **Herding** (score 37) may signal cautious underperformance relative to peers, but the lack of panic or FOMO suggests a more measured, narrative-driven approach.
Updated: 09/08/2026, 10:47 PM
What could change this?
👥 What the crowd believes
"Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics with a Buy rating and announces Price Target of $10."
"Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%"
"Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)"
"Aclaris Therapeutics reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of $(0.13) per share."
📈 6D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for ACRS reflects deep methodological disagreements about risk, valuation, and market timing. Walter Bagehot’s near-perfect score highlights his focus on liquidity and credit resilience, suggesting he’d see stability in the face of financial stress—an approach starkly contrasting with Howard Marks’ late-cycle warning, which flags the stock as risky given its perceived market positioning. Meanwhile, Philip Fisher’s near-zero score underscores his strict quality/growth criteria, while Peter Lynch’s mixed verdict hints at a stock where growth is already priced in, leaving little upside for his momentum-driven approach. The middle ground—seen in investors like Samuel Nelson or Jack Schwager—shows uncertainty, but even their neutral stances pale compared to Morgan Housel’s outright rejection, which prioritizes volatility tolerance over speculative bets.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 75
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 75
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 54
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 49
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 42
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 34
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 27
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 17
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 7
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 7 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
73.3%
Operating Margin
-975.9%
Net Margin
-829.6%
EBITDA Margin
-970.1%
ROE
-63.0%
ROA
-40.5%
ROIC
—
EPS
-$0.53
Cash
$19.96M
Total Debt
—
Current Ratio
3.36
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$5.50
Estimated Fair Value (DCF)
-$5.09
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-192.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-44.86M | $-41.16M |
| 2 | -3.1% | $-43.46M | $-36.58M |
| 3 | -1.2% | $-42.92M | $-33.14M |
| 4 | 0.6% | $-43.19M | $-30.59M |
| 5 | 2.5% | $-44.27M | $-28.77M |
Base FCF (last actual year)
$-47.22M
Terminal Value
$-698.03M
Present Value of Terminal Value
$-453.67M
Enterprise Value
$-623.92M
Net Debt
$0
Equity Value
$-623.92M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.84
Tangible Book Value per Share (Tangible NAV)
$0.84
Sentiment based on basic keywords (not AI) — 13 positive, 6 neutral, 1 negative out of the last 20 articles.
Yahoo · 15.9.2026
ChartMill · 14.9.2026
Benzinga · 14.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
Benzinga · 1.9.2026
MT Newswires · 1.9.2026
Benzinga · 25.8.2026
Benzinga · 25.8.2026
Benzinga · 25.8.2026
Zacks · 10.8.2026
GlobeNewswire · 6.8.2026
GlobeNewswire · 6.8.2026
Zacks · 6.8.2026
Associated Press · 6.8.2026
GlobeNewswire · 6.8.2026
Benzinga · 6.8.2026
Zacks · 1.7.2026
MarketBeat · 20.6.2026
Insider Monkey · 7.6.2026
Aclaris Therapeutics, Inc. (ACRS) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ACRS currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ACRS's estimated fair value is -$5.09, which is 192.6% below the current price of $5.50. This is one valuation model among several signals in the fair-value category, not a price target.
ACRS's technical score is 38/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 69.0%; Net income growth: 50.8%; Current ratio: 3.36.
Based on the real signals StockIQ computed: Estimated fair value: -$5.09 vs. price $5.50 (-192.6%); Operating margin: -975.9% (negative); Net margin: -829.6% (negative).
StockIQ has no recorded dividend payment history for ACRS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Kolbeck Roland Wilhelm | Exercise of Derivative Securities | 1.8.2026 | 36,375 | +36,375 | — |
| Kolbeck Roland Wilhelm | Exercise of Derivative Securities | 1.8.2026 | 36,375 | -36,375 | — |
| Kolbeck Roland Wilhelm | Tax Withholding in Shares | 1.8.2026 | 12,385 | -12,385 | $5.20 |
| Kolbeck Roland Wilhelm | Exercise of Derivative Securities | 1.8.2026 | 36,375 | +36,375 | — |
| Kolbeck Roland Wilhelm | Tax Withholding in Shares | 1.8.2026 | 23,990 | -12,385 | $5.20 |
| Kolbeck Roland Wilhelm | Exercise of Derivative Securities | 1.8.2026 | 109,125 | -36,375 | — |
| SCHIFF ANDREW N | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| Molineaux Christopher P. | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| MILANO VINCENT | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| MILANO VINCENT | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| GOWEN MAXINE | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| Molineaux Christopher P. | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| Humphries William D. | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| Mehra Anand | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| SCHIFF ANDREW N | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| Humphries William D. | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| Mehra Anand | Exercise of Derivative Securities | 5.6.2026 | 11,580 | +11,580 | — |
| GOWEN MAXINE | Exercise of Derivative Securities | 5.6.2026 | 11,580 | -11,580 | — |
| SCHIFF ANDREW N | Exercise of Derivative Securities | 5.6.2026 | 25,540 | +11,580 | — |
| SCHIFF ANDREW N | Exercise of Derivative Securities | 5.6.2026 | 0 | -11,580 | — |
| MILANO VINCENT | Exercise of Derivative Securities | 5.6.2026 | 28,896 | +11,580 | — |
| MILANO VINCENT | Exercise of Derivative Securities | 5.6.2026 | 0 | -11,580 | — |
| GOWEN MAXINE | Exercise of Derivative Securities | 5.6.2026 | 33,334 | +11,580 | — |
| GOWEN MAXINE | Exercise of Derivative Securities | 5.6.2026 | 0 | -11,580 | — |
| Mehra Anand | Exercise of Derivative Securities | 5.6.2026 | 726,403 | +11,580 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
15,180,778 shares short as of 2026-08-31 · vs. 13,774,975 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
40.5% of trading volume this week was short selling, vs. 38.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology